Clin2
NCT06943365Possibly a fitRecruiting

Role of Anti-TREK-1 Antibodies in Sudden Cardiac Arrest Without Blockage

Short-coupled Ventricular FibrillationIdiopathic Ventricular Fibrillation

Part of Heart & circulation clinical trials.

This study looks for a specific type of antibody (called anti-TREK-1) in the blood of people who have had a sudden cardiac arrest without a clear cause. It aims to understand if these antibodies play a role in the condition, which might help with future diagnosis or treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
300 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 years old or older.
  • You must have been diagnosed with sudden cardiac arrest without a blocked artery (called SCVF).
  • You must agree to give written permission to take part in the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07405229Recruiting· Phase 4
Medical treatment for idiopathic ventricular fibrillation patients

This study tests medical treatments for people who survived a cardiac arrest with a specific heart rhythm problem called idiopathic ventricular fibrillation. If your cardiac arrest was likely from a heart issue but not from clogged arteries, you might help find better treatments.

Copenhagen, Dr.
NCT07444931Recruiting
Predicting cardiac arrest risk in heart disease patients

This study looks at factors that may help predict sudden cardiac arrest in people with coronary artery disease. If you have a recent diagnosis of significant blockage or a heart attack, joining this trial could help improve risk assessment.

Hadera
NCT06804499Recruiting
Coronary artery disease and sudden cardiac arrest study

This study is for people with coronary artery disease (blocked arteries in the heart) who live in the Pirkanmaa area of Finland. It will collect information and blood samples to better understand heart disease and sudden cardiac arrest.

Tampere, Pirkanmaa
NCT07263139Recruiting· Phase 2
Testing AGP100 for CPVT heart condition

This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.

Oslo
NCT04404465Enrolling by invitation
Test blood/heart signals to understand atrial fibrillation changes

This study looks at early changes in the heart related to atrial fibrillation (AF) using health data and biomarkers. It aims to find better ways to predict or understand AF, especially around procedures like ablation or cardioversion.

San Francisco, California
NCT07020702Recruiting
Predicting sudden cardiac death risk in heart muscle disease

This study looks at how the heart's electrical signals can predict sudden cardiac arrest in people with a weakened heart muscle. It may help doctors identify who is at highest risk.

Clermont-Ferrand

Hear when a new Short-coupled Ventricular Fibrillation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.